Cochrane · systematic review · CD002229
Hormone therapy for preventing cardiovascular disease in post‐menopausal women
Boardman, HMP, Hartley, L, Eisinga, A, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
18
current version
GRADE rated
18
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 6 · 33.3%High 12 · 66.7%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsHormone therapy compared to placebo for primary prevention of cardiovascular disease in post‐menopausal women
Population: Post‐menopausal women without prior cardiovascular disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Death (all‐causes) Hormone therapy vs placebo | RR 1 [0.89, 1.12] | 8 studies · 34422 participants | High |
Death (cardiovascular causes) Hormone therapy vs placebo | RR 0.81 [0.47, 1.4] | 3 studies · 28353 participants | High |
Stroke Hormone therapy vs placebo | RR 1.32 [1.12, 1.56] | 4 studies · 28719 participants | High |
Venous thromboembolism Hormone therapy vs placebo | RR 1.92 [1.24, 2.99] | 6 studies · 33477 participants | Moderate Downgraded: inconsistency |
Pulmonary embolism Hormone therapy vs placebo | no estimate extracted | 3 studies · 31732 participants | Moderate Downgraded: inconsistency |
Hormone therapy compared to placebo for secondary prevention of cardiovascular disease in post‐menopausal women
Population: Post‐menopausal women with pre‐exisiting cardiovascular disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Death (all‐causes) Hormone therapy vs placebo | RR 1.04 [0.87, 1.24] | 7 studies · 5445 participants | High |
Death (cardiovascular causes) Hormone therapy vs placebo | RR 1 [0.78, 1.29] | 6 studies · 5259 participants | High |
Stroke Hormone therapy vs placebo | RR 1.09 [0.89, 1.33] | 5 studies · 5172 participants | Moderate Downgraded: imprecision |
Venous thromboembolism Hormone therapy vs placebo | RR 2.02 [1.13, 3.62] | 6 studies · 4399 participants | High |
Pulmonary embolism Hormone therapy vs placebo | RR 2.48 [0.92, 6.7] | 3 studies · 3920 participants | Moderate Downgraded: imprecision |
Hormone therapy commenced less than 10 years after the menopause for preventing cardiovascular disease in post‐menopausal women
Population: Post‐menopausal women
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Death (all‐causes) | RR 0.7 [0.52, 0.95] | 5 studies · 9088 participants | Moderate Downgraded: risk of bias |
Coronary heart disease (death from cardiovascular causes and non‐fatal myocardial infarction) | RR 0.52 [0.29, 0.96] | 4 studies · 8311 participants | Moderate Downgraded: risk of bias |
Stroke | RR 1.37 [0.8, 2.34] | 3 studies · 8143 participants | High |
Venous thromboembolism | RR 1.74 [1.11, 2.73] | 3 studies · 9838 participants | High |
Hormone therapy commenced more than 10 years after the menopause for preventing cardiovascular disease in post‐menopausal women
Population: Post‐menopausal women
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Death (all‐causes) | RR 1.06 [0.95, 1.18] | 12 studies · 27750 participants | High |
Coronary heart disease (death from cardiovascular causes and non‐fatal myocardial infarction) | RR 1.07 [0.96, 1.2] | 12 studies · 23491 participants | High |
Stroke | RR 1.21 [1.06, 1.38] | 8 studies · 22722 participants | High |
Venous thromboembolism | RR 1.96 [1.37, 2.8] | 9 studies · 27475 participants | High |